Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $130.66. The company's market cap stands at 162.22B, with a P/E ratio of 17.76 and a dividend yield of 2.4%.
As of 2026-05-20, Gilead Sciences(GILD) stock has fluctuated between $130.05 and $131.95. The current price stands at $130.66, placing the stock +0.5% above today's low and -1.0% off the high.
Gilead Sciences(GILD) shares are trading with a volume of 728.84K, against a daily average of 6.5M.
During the past year, Gilead Sciences(GILD) stock moved between $104.46 at its lowest and $157.29 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $104.46 at its lowest and $157.29 at its peak.
GILD News
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affe...
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target The company’s growth in the base business is expected to reach...
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target Published first on TheFly – the ultimate source for real-time...
Analyst ratings
75%
of 32 ratingsMore GILD News
...
Advertisement Stock performance snapshot and recent context Gilead Sciences (GILD) has seen its stock pull back recently, with the price declining about 7% ov...
Gilead Sciences (NasdaqGS:GILD) plans to present new liver disease data at the upcoming EASL Congress. The company will showcase pivotal Phase 3 results for Li...
Gilead (GILD) Sciences will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver Con...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.